Skip to main content

Treatment Clinical Trials for Breast Cancer

Review the breast cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 301-325 of 478

Magtrace for Delayed Sentinel Lymph Node Biopsy in Patients with Ductal Carcinoma In-Situ
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women with Breast Cancer, OFS Trial
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Radiation Therapy without Endocrine Therapy for Treatment in Older Patients with Stage IA-IB Estrogen Receptor Positive Breast Cancer, EMERALD Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Comparison of Adjuvant Endocrine Therapy and Accelerated Partial Breast Irradiation following Lumpectomy for the Treatment of Early-Stage Breast Cancer Patients Over 65, CAMERAN Study
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Zanidatamab before Surgery for the Treatment of Early Stage HER2/Neu Positive Breast Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Neoadjuvant Endocrine Therapy to Improve Surgical Outcomes in Stage II-III ER+ HER2- Invasive Lobular Breast Cancer
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
High Dose Radiation Therapy with Pembrolizumab and Chemotherapy for the Treatment of Patients with PD-L1 Positive Metastatic Triple Negative Breast Cancer
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Routine Cavity Shave Margins or Selective Shave Margins Using Savi Scout in Treating Stage I-II Invasive Breast Cancer or Stage 0 Breast Ductal Carcinoma in Situ
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
A Cancer Vaccine (STEMVAC) in Combination with Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
5 versus 9-Day Course of Whole Breast Radiation Therapy for the Treatment of Early-Stage Breast Cancer in Patients Who Have Undergo Lumpectomy, FAST NOVEMBER Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
A Vaccine (STEMVAC) with Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
A Sequential Treatment Plan for the Treatment of Hormone Positive Metastatic Breast Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Accelerated Super-Hypofractionated Breast Brachytherapy for Controlling Disease in Patients who have Undergone Lumpectomy for Breast Cancer, ASHBY Trial
Status: Active
Location: VCU Massey Comprehensive Cancer Center, Richmond, Virginia
Medication Switch versus Guideline-directed Intervention (Side Effect Management) in Reducing Side Effects of Aromatase Inhibitors in Estrogen Receptor Positive HER2 Negative Breast Ductal Carcinoma In Situ and Stage I-III Invasive Breast Cancer, SWIVEL Trial
Status: Active
Location: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
Ultra Hypofractionated Whole Breast Radiation Therapy with Simultaneous Tumor Area Boost after Surgery for the Treatment of Early-Stage Breast Cancer, H-ASSIST Trial
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy in Patients with Metastatic Triple Negative Breast Cancer
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Adaptive Therapy with Capecitabine for the Treatment of Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Status: Active
Location: Mayo Clinic in Arizona, Scottsdale, Arizona
Cemiplimab and Transarterial Radioembolization with Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Low Dose Capecitabine for the Treatment of Locally Advanced and Metastatic HER2 Negative Breast Cancer
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Neoadjuvant Letrozole with or without Abemaciclib in Hormone Receptor Positive Breast Cancer
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Olaparib with Ceralasertib for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Palbociclib and Pembrolizumab for the Treatment of Patients with Brain Metastases
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Fulvestrant and Neratinib, Alpelisib, Everolimus or Abemaciclib for the Treatment of Estrogen Receptor Positive HER2 Negative Metastatic or Locally Recurrent Breast Cancer Previously Treated with a CDK4/6 Inhibitor, GERTRUDE Trial
Status: Active
Location: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas